secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001437749-23-001616
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic sells Alphazyme equity interest for ~$1.27M, retains sublicense rights
-----------------------------------------------------------------------------

- Received approx. $1.27M from sale of Alphazyme equity interest.
- Non-exclusive sublicense remains; Dyadic gets milestone/royalty payments on C1-expressed products.
- Potential additional payments based on future sales of Alphazyme's existing products.
- Alphazyme Sale Agreement executed January 18, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/0001437749-23-001616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/dyai20230116_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-001616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer